Browse the evidence

Adding semaglutide to usual care in US adults without diabetes is projected to avert 358,400 major adverse cardiovascular events (MACE) at a cost of $148,100 per quality-adjusted life-year (QALY) gained.

Semaglutide may be a beneficial addition to treatment plans for eligible patients to reduce cardiovascular risks.

Tirzepatide is effective in glucose control and weight reduction.

Tirzepatide can be considered a viable option for improving glycemic control and aiding weight loss in diabetic patients.

A prolonged lapse in GLP-1 receptor agonist therapy warrants consideration of reinitiation at a reduced dose.

Practitioners should consider starting patients on a reduced dose after a significant therapy lapse.

Incretin agonist therapies improve type 2 diabetes outcomes and cardiovascular mortality.

Incretin agonists may be a viable alternative to surgery for managing diabetes and cardiovascular risks.

Tirzepatide is effective in reducing body weight and controlling blood glucose levels.

Tirzepatide can be considered a viable treatment option for patients struggling with weight and blood glucose management.

Carbohydrate-restricted diets (CRDs) significantly improved glycemic control, including glucose (SMD = -2.94 mg/dL), insulin (SMD = -8.19 pmol/L), and HOMA-IR (-0.54).

Practitioners may consider CRDs as an effective strategy for improving glycemic control in adults.

Drinking 1L or more water per day was associated with significantly increased odds of recovering from the metabolic syndrome over 12 mo (OR: 3.9, 95%CI: 1.7–8.8, p = 0.001).

Increasing water intake may enhance recovery from metabolic syndrome in overweight women.

48.2% of patients who were ineligible for transplant due to elevated body mass index achieved waitlist activation after successful weight loss.

Successful weight loss with semaglutide can enhance transplant eligibility for patients.

Semaglutide initiated 6 months post LSG results in significantly greater absolute weight loss of 14.03 ± 5.26 kg compared to 5.63 ± 6.25 kg in controls from 6 to 12 months post LSG (p < 0.0001).

Practitioners may consider semaglutide as an effective adjunct therapy for weight management in patients post-sleeve gastrectomy.

Semaglutide therapy leads to a higher percentage weight loss of 12.61% ± 4.11% compared to 4.84% ± 5.18% in controls from 6 to 12 months post LSG (p < 0.0001).

Semaglutide may be recommended for patients post-surgery to enhance weight loss outcomes.

At 12 months, total weight loss was higher in the treatment group (35.77% ± 8.35%) compared to controls (28.37% ± 7.41%; p < 0.0001).

The findings support the use of semaglutide for improved long-term weight management post-surgery.

Patients with a longer duration of GLP-1RA treatment are more likely to achieve successful weight reduction at follow-up of 12 months (OR = 1.014).

Practitioners should consider the duration of GLP-1RA treatment as a factor in achieving weight loss.

Using semaglutide is associated with successful weight reduction at the follow-up of 6 months (OR = 2.138).

Semaglutide may be a more effective option for weight reduction in patients treated with GLP-1RA.

GLP-1 receptor agonists produced greater weight loss among women (10.9%; 95% CI, 7.0%-14.8%) than men (6.8%; 95% CI, 4.6%-9.0%).

Practitioners should consider gender differences when prescribing GLP-1 receptor agonists for weight loss.

GLP-1-based medications can achieve up to 24% weight loss, aiding in the effective management of obesity and its complications.

Practitioners can consider GLP-1 medications as a viable option for weight management in obese patients.

Semaglutide, a GLP-1 receptor agonist, can lead to weight reductions of up to 15%.

Practitioners should consider the potential effectiveness of semaglutide for weight loss in patients.

Incretin-based therapies induced substantial weight loss, mostly from fat mass.

Practitioners can consider incretin-based therapies as effective options for promoting fat loss in T2D patients.

Broad access to semaglutide would result in 38,950 cardiovascular events avoided and 6,180 deaths avoided over a 10-year period.

Practitioners should consider the significant health benefits of prescribing semaglutide to eligible Medicare patients.

Incretin analogs (liraglutide, semaglutide, and tirzepatide) are effective for weight management in adults without diabetes, with percent weight loss ranging from 5.7% to 20.9%.

Healthcare providers can consider prescribing these agents for weight management in overweight or obese patients without diabetes.

GLP-1 receptor agonists provide glycemic and complication-risk reduction benefits for individuals with type 2 diabetes.

Practitioners can consider GLP-1 receptor agonists as effective treatment options for managing glycemic levels and reducing complications in type 2 diabetes patients.

Semaglutide leads to significantly higher overall weight loss compared to placebo and most other comparison treatments.

Semaglutide may be a viable option for practitioners looking to support weight loss in obese and overweight patients.

CagriSema is being marketed as a safe and potentially superior medication to lower both Hemoglobin A1c and body weight.

Practitioners may consider CagriSema as a treatment option for patients needing glycemic control and weight management.

Weight-loss medications, especially incretin mimetics, are effective for short- and long-term treatment of obesity-related hypertension.

Practitioners may consider prescribing incretin mimetics for effective management of obesity-related hypertension.

Orlistat and Liraglutide are currently available medication options for long-term obesity treatment in Germany.

Clinicians can prescribe Orlistat or Liraglutide for patients needing long-term obesity management.